INVESTOR INFORMATION

Pearko Therapeutics Inc. is a privately owned and operated biotechnology company committed to improving the care of patients with heart failure. Our top priority is to provide worldwide access to our Apelin Analog therapy through the global markets.

At this time, we are moving beyond the preclinical stages of development of our proprietary Apelin Analog technology to pursue clinical trials in accordance with Health Canada and the Food and Drug Administration (FDA), as well as approach the European Medicines Agency (EMA) for the launch of our therapy.

With your support, we can bring medical innovations to patients with cardiovascular disease.